GSK's cell therapy retreat hits another partner as drugmaker exits Immatics collaboration
It turns out that GSK’s broad retreat from cell therapies went even deeper than it let on.
As Immatics, which scored $50 million upfront from GSK back in 2020 to collaborate on two T cell receptor therapies for solid tumors, revealed in its Q3 update:
On October 24, 2022, GSK provided Immatics with notice of its decision to terminate their collaboration.
If the date looks familiar, that’s because it’s the same day Lyell put out word that GSK axed their cell therapy alliance, which came with $250 million upfront. The day after, Adaptimmune followed up with the news that GSK was also punting its NY-ESO and PRAME programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
